CL2013000002A1 - Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras. - Google Patents

Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras.

Info

Publication number
CL2013000002A1
CL2013000002A1 CL2013000002A CL2013000002A CL2013000002A1 CL 2013000002 A1 CL2013000002 A1 CL 2013000002A1 CL 2013000002 A CL2013000002 A CL 2013000002A CL 2013000002 A CL2013000002 A CL 2013000002A CL 2013000002 A1 CL2013000002 A1 CL 2013000002A1
Authority
CL
Chile
Prior art keywords
receptors
delivering
inflammatory response
endometrosis
allergy
Prior art date
Application number
CL2013000002A
Other languages
English (en)
Inventor
David F Woodward
Jose L Martos
Jenny W Wang
Hussi J Kangasmetsa
William C Carling
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2013000002A1 publication Critical patent/CL2013000002A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)

Abstract

Un compuesto derivado de un ácido 1-[(2-{[(alquil o aril)metil]oxi}halo o haloalquil fenil sustituido)alquil]-5-hidrocarbilo o ácido carboxílico hidrocarbil-1h-pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores DP1, FP, EP1, TP y/o EP4 entregando una respuesta inflamatoria general, entre otros.
CL2013000002A 2010-07-01 2013-01-02 Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras. CL2013000002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36075510P 2010-07-01 2010-07-01

Publications (1)

Publication Number Publication Date
CL2013000002A1 true CL2013000002A1 (es) 2013-05-31

Family

ID=44514984

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000002A CL2013000002A1 (es) 2010-07-01 2013-01-02 Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras.

Country Status (17)

Country Link
US (3) US8492424B2 (es)
EP (1) EP2588459B1 (es)
JP (1) JP5922116B2 (es)
KR (1) KR20130141434A (es)
CN (1) CN103038219B (es)
AR (1) AR082073A1 (es)
AU (1) AU2011272716B2 (es)
BR (1) BR112013000065A2 (es)
CA (1) CA2804194C (es)
CL (1) CL2013000002A1 (es)
CO (1) CO6680625A2 (es)
ES (1) ES2625355T3 (es)
MX (1) MX2013000170A (es)
RU (1) RU2013102967A (es)
SG (1) SG186886A1 (es)
TW (1) TW201206891A (es)
WO (1) WO2012003414A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8859606B2 (en) 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
EP2794574B1 (en) * 2011-12-21 2017-11-08 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2862266C (en) * 2011-12-27 2016-10-04 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2013101598A1 (en) * 2011-12-27 2013-07-04 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2885008B1 (en) 2012-08-15 2018-11-07 University Of Virginia Patent Foundation Compositions and methods for treating peripheral arterial disease
WO2014113814A1 (en) * 2013-01-21 2014-07-24 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2015066541A1 (en) 2013-10-31 2015-05-07 Allergan, Inc. 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1h-pyrazol-3-yl}propanoic acid in crystalline form and methods for use thereof
CN106146400A (zh) * 2015-03-20 2016-11-23 四川大学 苄基-1h-吡唑、苄基-1h-吡咯衍生物及其制备方法和用途
US10462745B2 (en) 2016-01-15 2019-10-29 Google Llc Systems and methods for extending battery life by monitoring device activity
CN107723304A (zh) * 2016-08-10 2018-02-23 中国科学院上海生命科学研究院 Prkar2a在炎症消退中的应用
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US7273883B2 (en) 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US6511999B2 (en) 2000-09-14 2003-01-28 Allergan, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US20070054951A1 (en) * 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
DE602004011966T2 (de) * 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
JP2013535424A (ja) 2013-09-12
EP2588459B1 (en) 2017-03-01
RU2013102967A (ru) 2014-08-10
US20130253028A1 (en) 2013-09-26
BR112013000065A2 (pt) 2019-09-24
JP5922116B2 (ja) 2016-05-24
SG186886A1 (en) 2013-02-28
AU2011272716A1 (en) 2013-02-07
US20140121258A1 (en) 2014-05-01
KR20130141434A (ko) 2013-12-26
CA2804194A1 (en) 2012-01-05
CA2804194C (en) 2019-03-05
CN103038219A (zh) 2013-04-10
EP2588459A1 (en) 2013-05-08
WO2012003414A1 (en) 2012-01-05
CN103038219B (zh) 2016-08-24
US20120165382A1 (en) 2012-06-28
AR082073A1 (es) 2012-11-07
ES2625355T3 (es) 2017-07-19
MX2013000170A (es) 2013-05-28
AU2011272716B2 (en) 2016-05-19
CO6680625A2 (es) 2013-05-31
US8492424B2 (en) 2013-07-23
TW201206891A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
CL2013000002A1 (es) Compuesto derivado de pirazol sustituido; y su uso para tratar enfermedades o condiciones mediadas por el/los receptores pd1, fp, ep1, tp y/o ep4 entregando una respuesta inflamatoria genral, tal com artritis reumatoide, psoriasis, dermatitis atopica, endometrosis, alergia, asma, entre otras.
SMT201600174B (it) Forme solide di acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]diossol-5-il)ciclopropancarbossammido)-3-metilpiridin-2-il)benzoico
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
IN2012DE00888A (es)
UY34092A (es) Nuevos compuestos como inhibidores de jak
MX2014004506A (es) Composiciones de tratamiento de baño autoadhesivas.
MX2014007254A (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2.
UA111084C2 (uk) Заміщені піколінові кислоти і піримідин-4-карбонові кислоти, спосіб їх одержання, а також їх застосування як гербіцидів і регуляторів росту рослин
ATE498616T1 (de) In ionischen flüssigkeiten erzeugte hydroxymethylfurfuralether und -ester
CO6852097A2 (es) Agentes de coalescencia amigables con el medio ambiente
UY33930A (es) Inhibidores novedosos de quinasas
UA113620C2 (xx) Композиція, що містить аморфну (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)оцтову кислоту
UA111827C2 (uk) Спосіб отримання інгенол-3-ангелату
EP3517611A3 (en) Methods for preparative in vitro cloning
IN2015DN02668A (es)
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CL2012000272A1 (es) Proceso para la preparacion de (9-diclorometileno-1,2,3,4-tetrahidro-1,4-metano-naftalen-5-il)-amida del acido 3-difluorometil-1-metil-1h-pirazol-4-carboxilico; y los compuestos intermediarios considerados.
CR20120630A (es) Nuevos procesos
CU20190098A7 (es) Compuesto derivado de carboxamida útil para inducir la condrogénesis
PE20150370A1 (es) Composiciones herbicidas que comprenden acido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenilo) piridina-2-carboxilico o un derivado del mismo y un sulfonilaminocarboniltriazolinona
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
CR20110589A (es) Compuestos y métodos para controlar hongos
IT1397912B1 (it) Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
UY33507A (es) Proceso para la preparacion de sales de enolato de 4-fluoro-2-hidroximetileno-3-oxo-butiratos